PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche. Approval for Evrysdi from the European Medicines Agency was received on March 30 for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. We are happy to see the rapid adoption of Evrysdi in the EU which speaks to the need for new treatments for SMA patients, said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. We are delighted that an effective at-home therapy will be available to SMA patients. We recognize that a large proportion of SMA patients in the EU are current
Who is lobbying in the Ethiopia conflict as Coons heads to Addis Ababa politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.
Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients
- Sustained or improved motor function was observed with 24 months of treatment -
- Patients and caregivers reported a greater ability to complete activities of daily livingwith increased independence -
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., March 16, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam) in children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) at the 2021 Muscular Dystrophy Association (MDA) Virtual and Scientific Conference. These results demonstrated that Evrysdi patients sustained or improved in motor function after 24 months of treatment. Furthermore, the patients and caregivers reported improvements in their ability to function independently as well
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) who switched from prednisone to EMFLAZA® (deflazacort) following the FDA approval. The primary reason the majority of patients chose to switch to EMFLAZA was a desire to delay disease progression to improve the benefit and tolerability. During the 6-months average follow-up after switching, physician-reported outcomes were consistent with EMFLAZA addressing the primary reasons for switching. Data were presented at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical and Scientific Conference.
SOUTH PLAINFIELD, N.J., Feb. 26, 2021 /PRNewswire/ PTC Therapeutics, Inc. , today announced that the European Medicines Agency Committee for Medicinal Products for Human Use has recommended the. | March 4, 2021